MedTrace Logo

Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.

NCT06417801 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2026-05-29

No results posted yet for this study

Summary

Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy) in comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Rodrigo Dienstmann · Oncoclínicas

  • Vladmir C. de Lima · FUNDAÇÃO ANTONIO PRUDENTE - A.C. CAMARGO CANCER CENTER

  • Tomas Reinert · IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE

  • Renata Bonadio · INSTITUTO D'OR DE PESQUISA E ENSINO - SÃO PAULO

  • Mayana Lopes · ENSINO E TERAPIA DE INOVAÇÃO CLÍNICA AMO - ÉTICA

  • Leandro Jonata C. de Oliveira · SOCIEDADE BENEFICENTE ISRAELITA BRASILEIRA HOSPITAL ALBERT EISNTEIN

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06417801 on ClinicalTrials.gov